Key result
Fibrinolytic agents are widely used for acute myocardial infarction but suffer from significant limitations including resistance to reperfusion, acute coronary reocclusion, and bleeding complications.
This review summarizes the mechanisms, clinical applications, and limitations of existing fibrinolytic agents, while highlighting ongoing research into novel thrombolytic therapies.
Answers are grounded in this paper and cite their sources.
Fibrinolytics' limitations warrant caution in AMI reperfusion; leaves open which novel agents will prove superior in trials.
Fibrinolytic (thrombolytic) agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin. Agents available for clinical use are: the physiologic tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA)--either in a single chain (scu-PA, prourokinase) or a two-chain (tcu-PA, urokinase) form, and the bacterial activator plasminogen streptokinase or its anisoylated complex with plasminogen (APSAC). Despite their widespread use, mainly in patients with acute myocardial infarction, all these agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications. Several lines of research towards improvement of thrombolytic agents are being explored, including the construction of mutants and variants of plasminogen activators, chimeric plasminogen activators, or plasminogen activators from animal (e.g. vampire bat) or bacterial (e.g. staphylokinase) origin. Pilot studies in patients with acute myocardial infarction have been performed with a few selected agents. Definition of their relative therapeutic benefit, or lack thereof, will require more detailed dose-finding studies, followed by randomized clinical trials against presently available thrombolytic agents.
No takes yet. Share an insight, caveat, or question.
Lijnen et al. (1995) conducted a review in Acute myocardial infarction. Fibrinolytic agents was evaluated. Fibrinolytic agents are widely used for acute myocardial infarction but suffer from significant limitations including resistance to reperfusion, acute coronary reocclusion, and bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: